Federation des caisses Desjardins du Quebec’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-500	Closed	-$750	–	2407
2023 Q1	$750	Hold	500	–	–	﹤0.01%	2180
2022 Q4	$500	Hold	500	–	–	﹤0.01%	2354
2022 Q3	$900	Hold	500	–	–	﹤0.01%	2357
2022 Q2	$1.45K	Hold	500	–	–	﹤0.01%	2351
2022 Q1	$1.38K	Hold	500	–	–	﹤0.01%	2405
2021 Q4	$2.33K	Buy	500 +250	+100%	+$1.56K	﹤0.01%	2337
2021 Q3	$2.13K	Buy	+250	New	+$3.53K	﹤0.01%	2399
2020 Q2	–	Sell	-300	Closed	-$2.32K	–	2299
2020 Q1	$2.32K	Buy	+300	New	+$3.67K	﹤0.01%	1974

Federation des caisses Desjardins du Quebec's TCRR Position: Q2 2023 in Review

Federation des caisses Desjardins du Quebec sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 500 shares — an estimated $750 sold.

Federation des caisses Desjardins du Quebec first reported a position in TCRR in Q1 2020 and held it in 8 quarters. The position peaked at $2.33K in Q4 2021. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

Federation des caisses Desjardins du Quebec reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Federation des caisses Desjardins du Quebec sold 500 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $750.
Federation des caisses Desjardins du Quebec first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2020 and held it in 8 quarters.
Federation des caisses Desjardins du Quebec's TCR2 Therapeutics Inc. Common Stock position peaked at $2.33K in Q4 2021.
0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q2 2023, filed 15 Aug 2024.